Display options
Cite
Ito D, Iuchi T, Kurihara S, et al. Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes. J Clin Med Res. 2015;7(9):694-9doi: 10.14740/jocmr2237w.
Ito, D., Iuchi, T., Kurihara, S., Inoue, I., Katayama, S., & Inukai, K. (2015). Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes. Journal of clinical medicine research, 7(9), 694-9. https://doi.org/10.14740/jocmr2237w
Ito, Daisuke, et al. "Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes." Journal of clinical medicine research vol. 7,9 (2015): 694-9. doi: https://doi.org/10.14740/jocmr2237w
Ito D, Iuchi T, Kurihara S, Inoue I, Katayama S, Inukai K. Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes. J Clin Med Res. 2015 Sep;7(9):694-9. doi: 10.14740/jocmr2237w. Epub 2015 Jul 24. PMID: 26251684; PMCID: PMC4522987.
Copy Download .nbib Format: NLM
Share it on

J Clin Med Res. 2015 Sep;7(9):694-9. doi: 10.14740/jocmr2237w. Epub 2015 Jul 24.

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.

Journal of clinical medicine research

Daisuke Ito, Takujiro Iuchi, Susumu Kurihara, Ikuo Inoue, Shigehiro Katayama, Kouichi Inukai

Affiliations

  1. Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan ; Division of Internal Medicine, Ogawa Red Cross Hospital, 1525, Ogawa, Ogawa, Hiki-gun, Saitama 355-0397, Japan.
  2. Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
  3. Division of Diabetes and Endocrinology, Higashiyamato Hospital, 1-13-12, Nangai, Higashiyamato, Tokyo 207-0014, Japan.

PMID: 26251684 PMCID: PMC4522987 DOI: 10.14740/jocmr2237w

Abstract

BACKGROUND: Liraglutide was first released in Japan as a long-acting once-daily glucagon-like peptide-1 receptor agonist. The maximum dose in Japan is 0.9 mg/day, which is half of that used in the United States and the European Union (1.8 mg/day). The efficacy of this maximum allowable dose of liraglutide for Japanese patients and the profiles of those patients for whom this agent should be recommended remain unclear.

METHODS: This study aimed to examine the effective use of liraglutide in Japanese type 2 diabetic patients. We administered liraglutide to 60 patients, who had been managed with oral hypoglycemic agents or diet and exercise therapy only, during a period of 6 months.

RESULTS: Though HbA1c levels significantly decreased, by approximately 1.5%, after 6 months of liraglutide administration, no significant changes in body weights were observed. The 0.6 mg dose was effective in approximately 40% of patients. In contrast, the effects of a dose increase from 0.6 mg to 0.9 mg were small. The greatest efficacy, as shown by a 2.5% HbA1c decrease, was achieved in non-obese patients. Thus, efficacy decreased as the degree of obesity increased. In addition, efficacy was higher in patients who had a diabetes duration of less than 10 years and was also higher in the group that had a low sulfonylurea (SU) index, when we define the SU index as mg/glimepiride × years of treatment.

CONCLUSIONS: As appetite suppressions and associated decreases in body weights were not observed in obese patients, the efficacy of liraglutide at 0.9 mg did not appear to be high. Rather, it appeared to be highly effective for patients who were non-obese and for whom amelioration of blood glucose elevations could be anticipated via the stimulation of insulin secretion. Therefore, we found that liraglutide at doses of 0.9 mg was highly effective in non-obese patients who were in the early stages of diabetes and was particularly effective in patients who had not yet been administered SU agents.

Keywords: Body weight; GLP-1 receptor agonist; Incretin; Liraglutide; Long-acting; Type 2 diabetes

References

  1. J Clin Med Res. 2014 Apr;6(2):138-44 - PubMed
  2. J Clin Med Res. 2015 May;7(5):303-7 - PubMed
  3. Diabetes Res Clin Pract. 2008 Aug;81(2):161-8 - PubMed
  4. J Clin Med Res. 2014 Apr;6(2):127-32 - PubMed
  5. Diabetes Obes Metab. 2010 Apr;12(4):341-7 - PubMed
  6. J Diabetes Investig. 2011 Aug 2;2(4):280-6 - PubMed
  7. Am J Physiol. 1998 Nov;275(5 Pt 1):G984-92 - PubMed
  8. Science. 1998 Aug 21;281(5380):1161-2 - PubMed
  9. Lancet. 2009 Jul 4;374(9683):39-47 - PubMed
  10. J Clin Med Res. 2012 Aug;4(4):251-8 - PubMed
  11. Gastroenterology. 2007 May;132(6):2131-57 - PubMed
  12. J Clin Invest. 2014 Jun;124(6):2456-63 - PubMed
  13. Diabetes Care. 2009 Jan;32(1):84-90 - PubMed
  14. Diabetologia. 2009 Oct;52(10):2046-55 - PubMed
  15. J Diabetes Investig. 2011 Nov 30;2(6):441-7 - PubMed
  16. Diabetes Technol Ther. 2011 Nov;13(11):1145-54 - PubMed
  17. Nat Rev Endocrinol. 2012 Dec;8(12):728-42 - PubMed
  18. J Clin Med Res. 2014 Oct;6(5):327-35 - PubMed
  19. J Clin Endocrinol Metab. 1986 Aug;63(2):492-8 - PubMed
  20. J Diabetes Investig. 2013 Mar 18;4(2):108-30 - PubMed
  21. Annu Rev Pharmacol Toxicol. 2010;50:355-75 - PubMed
  22. Trends Mol Med. 2008 Apr;14(4):161-8 - PubMed
  23. Lancet. 2011 Jul 9;378(9786):182-97 - PubMed
  24. Lancet. 2006 Nov 11;368(9548):1696-705 - PubMed
  25. J Clin Pharmacol. 2010 Aug;50(8):886-94 - PubMed
  26. Curr Med Res Opin. 2010 May;26(5):1013-22 - PubMed
  27. J Clin Invest. 2014 Oct;124(10):4473-88 - PubMed
  28. Cell Metab. 2006 Mar;3(3):153-65 - PubMed
  29. Diabetes Res Clin Pract. 2008 Feb;79(2):291-8 - PubMed
  30. Lancet. 2009 Feb 7;373(9662):473-81 - PubMed
  31. Diabet Med. 2009 Mar;26(3):268-78 - PubMed
  32. Diabetes. 2011 May;60(5):1561-5 - PubMed
  33. J Clin Med Res. 2013 Jun;5(3):217-21 - PubMed
  34. Diabetes Care. 2009 Jul;32(7):1224-30 - PubMed

Publication Types